Validation of risk prediction models for the development of HBV-related HCC: A retrospective multi-center 10-year followup cohort study

Yeon Seok Seo, Byoung Kuk Jang, Soon Ho Um, Jae Seok Hwang, Kwang Hyub Han, Sang Gyune Kim, Kwan Sik Lee, Seung Up Kim, Young Seok Kim, Jung Il Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Recently, modified REACH-B (mREACH-B) risk prediction model for hepatocellular carcinoma (HCC) development was proposed. We validated the accuracy of the mREACH-B model and compared its accuracy with those of other prediction models. Between 2006 and 2012, 1,241 patients with chronic hepatitis B (CHB) were recruited. All patients underwent transient elastography at enrollment. The median age of the study population (840 males, 401 females) was 49 years. The median PAGE-B, LSMHCC, and mREACH-B values were 10, 10, and 8, respectively. Among patients without cirrhosis (n = 940, 75.7%), the median REACH-B value was 9. During the follow-up period (median 77.4 months), 66 (5.3%) and 83 (6.7%) patients developed HCC and liver-related events (LRE), respectively. Higher liver stiffness (LS) independently predicted HCC (hazard ratio [HR] = 1.047) and LRE development (HR = 1.047) (all P < 0.05). The mREACH-B significantly predicted HCC (AUC = 0.824 at 3-year and 0.750 at 5-year) and LRE development (AUC = 0.782 at 3-year and 0.739 at 5-year) (all P < 0.001) and it performed similarly or significantly better than the PAGE-B and LSM-HCC (AUC = 0.715-0.809 at 3-year and 0.719-0.742 at 5-year for HCC; AUC = 0.704-0.777 at 3-year and 0.721-0.735 at 5-year for LRE). Among patients without cirrhosis, mREACH-B predicted HCC (AUC = 0.803 vs. 0.654-0.816 at 3-year and 0.684 vs. 0.639-0.738 at 5-year) and LRE development (AUC = 0.734 vs. 0.619-0.789 at 3-year and 0.674 vs. 0.626-0.729 at 5-year) similarly to PAGE-B, REACH-B, and LSM-HCC. mREACH-B appropriately predicted HCC and LRE development in patients with CHB and showed similar or superior accuracy to those of PAGE-B, REACH-B, and LSM-HCC.

Original languageEnglish
Pages (from-to)113213-113224
Number of pages12
JournalOncotarget
Volume8
Issue number68
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Hepatocellular Carcinoma
Cohort Studies
Area Under Curve
Liver
Chronic Hepatitis B
Fibrosis
Elasticity Imaging Techniques
Population

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Seo, Yeon Seok ; Jang, Byoung Kuk ; Um, Soon Ho ; Hwang, Jae Seok ; Han, Kwang Hyub ; Kim, Sang Gyune ; Lee, Kwan Sik ; Kim, Seung Up ; Kim, Young Seok ; Lee, Jung Il. / Validation of risk prediction models for the development of HBV-related HCC : A retrospective multi-center 10-year followup cohort study. In: Oncotarget. 2017 ; Vol. 8, No. 68. pp. 113213-113224.
@article{2c0816d840e546508bffe72322756aa4,
title = "Validation of risk prediction models for the development of HBV-related HCC: A retrospective multi-center 10-year followup cohort study",
abstract = "Recently, modified REACH-B (mREACH-B) risk prediction model for hepatocellular carcinoma (HCC) development was proposed. We validated the accuracy of the mREACH-B model and compared its accuracy with those of other prediction models. Between 2006 and 2012, 1,241 patients with chronic hepatitis B (CHB) were recruited. All patients underwent transient elastography at enrollment. The median age of the study population (840 males, 401 females) was 49 years. The median PAGE-B, LSMHCC, and mREACH-B values were 10, 10, and 8, respectively. Among patients without cirrhosis (n = 940, 75.7{\%}), the median REACH-B value was 9. During the follow-up period (median 77.4 months), 66 (5.3{\%}) and 83 (6.7{\%}) patients developed HCC and liver-related events (LRE), respectively. Higher liver stiffness (LS) independently predicted HCC (hazard ratio [HR] = 1.047) and LRE development (HR = 1.047) (all P < 0.05). The mREACH-B significantly predicted HCC (AUC = 0.824 at 3-year and 0.750 at 5-year) and LRE development (AUC = 0.782 at 3-year and 0.739 at 5-year) (all P < 0.001) and it performed similarly or significantly better than the PAGE-B and LSM-HCC (AUC = 0.715-0.809 at 3-year and 0.719-0.742 at 5-year for HCC; AUC = 0.704-0.777 at 3-year and 0.721-0.735 at 5-year for LRE). Among patients without cirrhosis, mREACH-B predicted HCC (AUC = 0.803 vs. 0.654-0.816 at 3-year and 0.684 vs. 0.639-0.738 at 5-year) and LRE development (AUC = 0.734 vs. 0.619-0.789 at 3-year and 0.674 vs. 0.626-0.729 at 5-year) similarly to PAGE-B, REACH-B, and LSM-HCC. mREACH-B appropriately predicted HCC and LRE development in patients with CHB and showed similar or superior accuracy to those of PAGE-B, REACH-B, and LSM-HCC.",
author = "Seo, {Yeon Seok} and Jang, {Byoung Kuk} and Um, {Soon Ho} and Hwang, {Jae Seok} and Han, {Kwang Hyub} and Kim, {Sang Gyune} and Lee, {Kwan Sik} and Kim, {Seung Up} and Kim, {Young Seok} and Lee, {Jung Il}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.22375",
language = "English",
volume = "8",
pages = "113213--113224",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "68",

}

Validation of risk prediction models for the development of HBV-related HCC : A retrospective multi-center 10-year followup cohort study. / Seo, Yeon Seok; Jang, Byoung Kuk; Um, Soon Ho; Hwang, Jae Seok; Han, Kwang Hyub; Kim, Sang Gyune; Lee, Kwan Sik; Kim, Seung Up; Kim, Young Seok; Lee, Jung Il.

In: Oncotarget, Vol. 8, No. 68, 01.01.2017, p. 113213-113224.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Validation of risk prediction models for the development of HBV-related HCC

T2 - A retrospective multi-center 10-year followup cohort study

AU - Seo, Yeon Seok

AU - Jang, Byoung Kuk

AU - Um, Soon Ho

AU - Hwang, Jae Seok

AU - Han, Kwang Hyub

AU - Kim, Sang Gyune

AU - Lee, Kwan Sik

AU - Kim, Seung Up

AU - Kim, Young Seok

AU - Lee, Jung Il

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Recently, modified REACH-B (mREACH-B) risk prediction model for hepatocellular carcinoma (HCC) development was proposed. We validated the accuracy of the mREACH-B model and compared its accuracy with those of other prediction models. Between 2006 and 2012, 1,241 patients with chronic hepatitis B (CHB) were recruited. All patients underwent transient elastography at enrollment. The median age of the study population (840 males, 401 females) was 49 years. The median PAGE-B, LSMHCC, and mREACH-B values were 10, 10, and 8, respectively. Among patients without cirrhosis (n = 940, 75.7%), the median REACH-B value was 9. During the follow-up period (median 77.4 months), 66 (5.3%) and 83 (6.7%) patients developed HCC and liver-related events (LRE), respectively. Higher liver stiffness (LS) independently predicted HCC (hazard ratio [HR] = 1.047) and LRE development (HR = 1.047) (all P < 0.05). The mREACH-B significantly predicted HCC (AUC = 0.824 at 3-year and 0.750 at 5-year) and LRE development (AUC = 0.782 at 3-year and 0.739 at 5-year) (all P < 0.001) and it performed similarly or significantly better than the PAGE-B and LSM-HCC (AUC = 0.715-0.809 at 3-year and 0.719-0.742 at 5-year for HCC; AUC = 0.704-0.777 at 3-year and 0.721-0.735 at 5-year for LRE). Among patients without cirrhosis, mREACH-B predicted HCC (AUC = 0.803 vs. 0.654-0.816 at 3-year and 0.684 vs. 0.639-0.738 at 5-year) and LRE development (AUC = 0.734 vs. 0.619-0.789 at 3-year and 0.674 vs. 0.626-0.729 at 5-year) similarly to PAGE-B, REACH-B, and LSM-HCC. mREACH-B appropriately predicted HCC and LRE development in patients with CHB and showed similar or superior accuracy to those of PAGE-B, REACH-B, and LSM-HCC.

AB - Recently, modified REACH-B (mREACH-B) risk prediction model for hepatocellular carcinoma (HCC) development was proposed. We validated the accuracy of the mREACH-B model and compared its accuracy with those of other prediction models. Between 2006 and 2012, 1,241 patients with chronic hepatitis B (CHB) were recruited. All patients underwent transient elastography at enrollment. The median age of the study population (840 males, 401 females) was 49 years. The median PAGE-B, LSMHCC, and mREACH-B values were 10, 10, and 8, respectively. Among patients without cirrhosis (n = 940, 75.7%), the median REACH-B value was 9. During the follow-up period (median 77.4 months), 66 (5.3%) and 83 (6.7%) patients developed HCC and liver-related events (LRE), respectively. Higher liver stiffness (LS) independently predicted HCC (hazard ratio [HR] = 1.047) and LRE development (HR = 1.047) (all P < 0.05). The mREACH-B significantly predicted HCC (AUC = 0.824 at 3-year and 0.750 at 5-year) and LRE development (AUC = 0.782 at 3-year and 0.739 at 5-year) (all P < 0.001) and it performed similarly or significantly better than the PAGE-B and LSM-HCC (AUC = 0.715-0.809 at 3-year and 0.719-0.742 at 5-year for HCC; AUC = 0.704-0.777 at 3-year and 0.721-0.735 at 5-year for LRE). Among patients without cirrhosis, mREACH-B predicted HCC (AUC = 0.803 vs. 0.654-0.816 at 3-year and 0.684 vs. 0.639-0.738 at 5-year) and LRE development (AUC = 0.734 vs. 0.619-0.789 at 3-year and 0.674 vs. 0.626-0.729 at 5-year) similarly to PAGE-B, REACH-B, and LSM-HCC. mREACH-B appropriately predicted HCC and LRE development in patients with CHB and showed similar or superior accuracy to those of PAGE-B, REACH-B, and LSM-HCC.

UR - http://www.scopus.com/inward/record.url?scp=85038851176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038851176&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.22375

DO - 10.18632/oncotarget.22375

M3 - Article

AN - SCOPUS:85038851176

VL - 8

SP - 113213

EP - 113224

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 68

ER -